Report
-
Roche reports positive study of Herceptin given by subcutaneous injection
Phase 3 study of a quicker route of administration shows comparable results to intravenous Herceptin.
Report | 18 October 2011
-
Biogen Idec, Abbott report positive results from trial of daclizumab HYP
Biogen Idec and Abbott announced positive top-line results from SELECT, a global, registrational phase 2b clinical trial designed to evaluate the investigational compound daclizumab high-yield process (DAC HYP) in people with relapsing-remitting mult…
Report | 09 August 2011
-
Abbott reports interim phase 3 results of advanced Parkinson's treatment
In a 54-week study, after 12 weeks of treatment with levodopa-carbidopa intestinal gel, patients reported improvement in motor symptoms.
Report | 09 June 2011
-
Kowa reports efficacy and safety of Rho kinase inhibitor
Kowa Company Ltd announced the results of two clinical studies and a non-clinical study of a drug candidate for glaucoma and ocular hypertension (K-115). The results were presented as three posters at The Association for Research in Vision and Ophtha…
Report | 11 May 2011
-
Abbott reports strong growth in emerging markets
Healthy performance across Abbott's diverse businesses and emerging markets expansion drove strong and consistent growth in 2010, Chairman and Chief Executive Officer Miles D White told shareholders at the company's annual meeting. "We continued t…
Report | 02 May 2011
-
Sanofi-aventis and Regeneron report positive phase 3 results with zaltrap
Sanofi-aventis and Regeneron Pharmaceuticals Inc announced positive results from the phase 3 velour trial evaluating the investigational agent zaltrap. Zaltrap (aflibercept), also known as VEGF Trap, in combination with the folfiri chemotherapy regim…
Report | 27 April 2011
-
Roche tops R&D spending in latest Research and Markets report
Research and Markets has announced the addition of the "Top 20 Company Pipelines 2010" report to their offering. Pharmaceutical companies remain on an upward R&D trend through 2010. More than 9,000 new drugs were added to the pipeline last year, …
Report | 21 March 2011
-
Sanofi-aventis, Regeneron report phase 3 lung cancer treatment trial results
Sanofi-aventis and Regeneron Pharmaceuticals Inc announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC). The data showed that …
Report | 11 March 2011
-
Two Fold: Web reporting module
The web reporting module is integrated into the Qualoupe LIMS solution and runs on a concurrent licence basis. This allows contract laboratories or manufacturing companies to access and run LIMS reports on demand in a more cost-efficient way. Qu…
Report | 01 March 2011
-
Bayer, Regeneron report positive results for VEGF trap-eye
Bayer HealthCare and Regeneron Pharmaceuticals report positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two phase 3 studies in patients with macular edema d…
Report | 01 March 2011
